Perceived usefulness of generative AI–based digital therapeutics and women’s intention to adopt: A cross-sectional PLS-SEM study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Women’s Perceived Usefulness of Generative AI–Based Digital Therapeutics and Their Adoption Intentions: A Cross-Sectional PLS-SEM Analysis

  • By

  • Yun-Jeong Jeong

  • Jang Mook Kim

  • Chunghun Ha

  • Seongdae Kim

  • October 12, 2026

Share

Clinical Scorecard: Women’s Perceived Usefulness of Generative AI–Based Digital Therapeutics and Their Adoption Intentions: A Cross-Sectional PLS-SEM Analysis

At a Glance

CategoryDetail
ConditionAcceptance of generative AI–based digital therapeutics (DTx)
Key MechanismsThe introduction describes DTx as software-delivered, evidence-based therapeutic devices intended to prevent, manage, or treat disease. It states that generative AI may be incorporated into DTx to deliver therapeutic interventions.
Target PopulationWomen; the introduction discusses gendered social and temporal constraints and states that the analysis focuses on DTx for prevention and management, therapeutic applications, and medication optimization.
Care SettingThe introduction discusses the shift toward digitally mediated care during the COVID-19 pandemic and describes DTx as intended for patient participation in automated therapeutic processes.

Key Highlights

  • The introduction defines DTx as software-delivered, evidence-based therapeutic devices intended to prevent, manage, or treat disease.
  • It describes generative AI as technology that produces user-directed outputs and may be incorporated into DTx to deliver therapeutic interventions.
  • The authors frame women’s social and temporal constraints as context for examining technology acceptance.
  • The stated analysis scope includes DTx for prevention and management, therapeutic applications, and medication optimization.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • The introduction reports concerns about medical liability, safety, and efficacy in non-face-to-face care.
        • The introduction states that clinical evidence is required for DTx regardless of intended purpose.

        Patient & Prescribing Data

        The introduction identifies women as the population of interest. The supplied excerpt does not report sample size or participant characteristics.

        The stated analysis scope includes DTx intended for prevention and management, therapeutic applications, and medication optimization. The supplied excerpt does not provide prescribing instructions or treatment outcomes.

        Clinical Best Practices

          Related Resources & Content

            Original Source(s)

            Related Content